Real-time near-body drug screening during autopsy I

use of the Randox biochip drugs of abuse DOA I and DOA II immunoassays

Poppy McLaughlin, Derrick Pounder, Peter Maskell, David Osselton

    Research output: Contribution to journalArticle

    7 Citations (Scopus)

    Abstract

    Screening for drugs of abuse is widely employed as part of forensic toxicology investigations. The nature of specimens collected at autopsy varies depending on local customs, the case circumstances, and the condition of the cadaver. It is generally accepted that wherever possible specimens of peripheral blood, liver, stomach contents, vitreous humor, and muscle can be useful for toxicological analysis. In some countries, legislation or religious custom may mitigate against the removal of postmortem tissue unless shown to be necessary. The availability of a sensitive and broad ranging near-body screening test may provide a useful tool to assist pathologists in making decisions regarding the retention of tissues for toxicology analysis. We describe the performance of the Randox drugs-of-abuse (DOA) arrays, DOA I and DOA II, for near-body screening using whole blood, urine, vitreous humor, liver, and psoas major muscle. Samples were obtained from 106 autopsies and screened for the presence of amphetamine, barbiturates, benzodiazepines, benzoylecgonine, buprenorphine, cannabinoids, fentanyl, ketamine, lysergic acid diethylamide, methadone, methamphetamine, methaqualone, methylenedioxymethylamphetamine (Ecstasy), opiates, oxycodone, phencyclidine, and propoxyphene in the mortuary whilst the postmortem was being performed. Blood from each case underwent confirmatory analysis using either gas chromatography-mass spectrometry, liquid chromatography with tandem mass spectrometry or diode array detection. Excellent agreement between the near-body screening tests on a variety of tissues and confirmatory analyses in blood was obtained.
    Original languageEnglish
    Pages (from-to)1-6
    Number of pages6
    JournalForensic Toxicology
    Early online date10 Aug 2012
    DOIs
    Publication statusPublished - 2012

    Fingerprint

    Biochips
    Preclinical Drug Evaluations
    Street Drugs
    Immunoassay
    Autopsy
    Screening
    Blood
    Vitreous Body
    Tissue
    Pharmaceutical Preparations
    Liver
    Toxicology
    Mass spectrometry
    Muscle
    Opiate Alkaloids
    Methaqualone
    Forensic Toxicology
    Dextropropoxyphene
    Psoas Muscles
    Oxycodone

    Cite this

    McLaughlin, Poppy ; Pounder, Derrick ; Maskell, Peter ; Osselton, David. / Real-time near-body drug screening during autopsy I : use of the Randox biochip drugs of abuse DOA I and DOA II immunoassays. In: Forensic Toxicology. 2012 ; pp. 1-6.
    @article{ac0a4c081d8a40c88fe44ab27899de1a,
    title = "Real-time near-body drug screening during autopsy I: use of the Randox biochip drugs of abuse DOA I and DOA II immunoassays",
    abstract = "Screening for drugs of abuse is widely employed as part of forensic toxicology investigations. The nature of specimens collected at autopsy varies depending on local customs, the case circumstances, and the condition of the cadaver. It is generally accepted that wherever possible specimens of peripheral blood, liver, stomach contents, vitreous humor, and muscle can be useful for toxicological analysis. In some countries, legislation or religious custom may mitigate against the removal of postmortem tissue unless shown to be necessary. The availability of a sensitive and broad ranging near-body screening test may provide a useful tool to assist pathologists in making decisions regarding the retention of tissues for toxicology analysis. We describe the performance of the Randox drugs-of-abuse (DOA) arrays, DOA I and DOA II, for near-body screening using whole blood, urine, vitreous humor, liver, and psoas major muscle. Samples were obtained from 106 autopsies and screened for the presence of amphetamine, barbiturates, benzodiazepines, benzoylecgonine, buprenorphine, cannabinoids, fentanyl, ketamine, lysergic acid diethylamide, methadone, methamphetamine, methaqualone, methylenedioxymethylamphetamine (Ecstasy), opiates, oxycodone, phencyclidine, and propoxyphene in the mortuary whilst the postmortem was being performed. Blood from each case underwent confirmatory analysis using either gas chromatography-mass spectrometry, liquid chromatography with tandem mass spectrometry or diode array detection. Excellent agreement between the near-body screening tests on a variety of tissues and confirmatory analyses in blood was obtained.",
    author = "Poppy McLaughlin and Derrick Pounder and Peter Maskell and David Osselton",
    note = "Copyright 2012 Elsevier B.V., All rights reserved.",
    year = "2012",
    doi = "10.1007/s11419-012-0149-2",
    language = "English",
    pages = "1--6",
    journal = "Forensic Toxicology",
    issn = "1860-8965",
    publisher = "Springer Verlag",

    }

    Real-time near-body drug screening during autopsy I : use of the Randox biochip drugs of abuse DOA I and DOA II immunoassays. / McLaughlin, Poppy; Pounder, Derrick; Maskell, Peter; Osselton, David.

    In: Forensic Toxicology, 2012, p. 1-6.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Real-time near-body drug screening during autopsy I

    T2 - use of the Randox biochip drugs of abuse DOA I and DOA II immunoassays

    AU - McLaughlin, Poppy

    AU - Pounder, Derrick

    AU - Maskell, Peter

    AU - Osselton, David

    N1 - Copyright 2012 Elsevier B.V., All rights reserved.

    PY - 2012

    Y1 - 2012

    N2 - Screening for drugs of abuse is widely employed as part of forensic toxicology investigations. The nature of specimens collected at autopsy varies depending on local customs, the case circumstances, and the condition of the cadaver. It is generally accepted that wherever possible specimens of peripheral blood, liver, stomach contents, vitreous humor, and muscle can be useful for toxicological analysis. In some countries, legislation or religious custom may mitigate against the removal of postmortem tissue unless shown to be necessary. The availability of a sensitive and broad ranging near-body screening test may provide a useful tool to assist pathologists in making decisions regarding the retention of tissues for toxicology analysis. We describe the performance of the Randox drugs-of-abuse (DOA) arrays, DOA I and DOA II, for near-body screening using whole blood, urine, vitreous humor, liver, and psoas major muscle. Samples were obtained from 106 autopsies and screened for the presence of amphetamine, barbiturates, benzodiazepines, benzoylecgonine, buprenorphine, cannabinoids, fentanyl, ketamine, lysergic acid diethylamide, methadone, methamphetamine, methaqualone, methylenedioxymethylamphetamine (Ecstasy), opiates, oxycodone, phencyclidine, and propoxyphene in the mortuary whilst the postmortem was being performed. Blood from each case underwent confirmatory analysis using either gas chromatography-mass spectrometry, liquid chromatography with tandem mass spectrometry or diode array detection. Excellent agreement between the near-body screening tests on a variety of tissues and confirmatory analyses in blood was obtained.

    AB - Screening for drugs of abuse is widely employed as part of forensic toxicology investigations. The nature of specimens collected at autopsy varies depending on local customs, the case circumstances, and the condition of the cadaver. It is generally accepted that wherever possible specimens of peripheral blood, liver, stomach contents, vitreous humor, and muscle can be useful for toxicological analysis. In some countries, legislation or religious custom may mitigate against the removal of postmortem tissue unless shown to be necessary. The availability of a sensitive and broad ranging near-body screening test may provide a useful tool to assist pathologists in making decisions regarding the retention of tissues for toxicology analysis. We describe the performance of the Randox drugs-of-abuse (DOA) arrays, DOA I and DOA II, for near-body screening using whole blood, urine, vitreous humor, liver, and psoas major muscle. Samples were obtained from 106 autopsies and screened for the presence of amphetamine, barbiturates, benzodiazepines, benzoylecgonine, buprenorphine, cannabinoids, fentanyl, ketamine, lysergic acid diethylamide, methadone, methamphetamine, methaqualone, methylenedioxymethylamphetamine (Ecstasy), opiates, oxycodone, phencyclidine, and propoxyphene in the mortuary whilst the postmortem was being performed. Blood from each case underwent confirmatory analysis using either gas chromatography-mass spectrometry, liquid chromatography with tandem mass spectrometry or diode array detection. Excellent agreement between the near-body screening tests on a variety of tissues and confirmatory analyses in blood was obtained.

    UR - http://www.scopus.com/inward/record.url?scp=84864564272&partnerID=8YFLogxK

    U2 - 10.1007/s11419-012-0149-2

    DO - 10.1007/s11419-012-0149-2

    M3 - Article

    SP - 1

    EP - 6

    JO - Forensic Toxicology

    JF - Forensic Toxicology

    SN - 1860-8965

    ER -